PapersPMID:24366103
Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.
- findings
- 2
- compound
- 1
- endpoints
- 2
- Study, every finding
- RCT
- Dose studied, every finding
- inosine 500 mg capsules, started at 1 capsule twice daily and titrated up to 2 capsules three times daily (maximum 3 g/day) to serum urate 6.1-7.0 or 7.1-8.0 mg/dL; mean doses 1.18 and 1.51 g/day; up to 24 months
No finding here moved its endpoint.
What did not
How to read these marks →“For example, serial vital signs, serum assays and ECGs showed no effect of inosine on blood pressure (eTables 5 and 6), body mass index (BMI; eTable 7), serum glucose and cholesterol (eTables 8), or electrocardiographic parameters (eTable 9).”
- Population
- Adults with early Parkinson disease not yet requiring symptomatic treatment, serum urate below about 6 mg/dL, without gout, urolithiasis, or cardiovascular or renal disease, at US Parkinson Study Group sites; both inosine arms (titrated to mild or moderate serum urate elevation) against placebo; hydration encouraged in all arms
- No detected effect on urine pH
moderate
“Need for alkalinization was rare because urine pH was unaffected by inosine (eTables 2 and 3).”
- Population
- Adults with early Parkinson disease not yet requiring symptomatic treatment, serum urate below about 6 mg/dL, without gout, urolithiasis, or cardiovascular or renal disease, at US Parkinson Study Group sites; both inosine arms against placebo; urine pH self-monitored at least daily for the first 12 weeks, with potassium citrate alkalinisation in any arm for persistently acidic urine
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- adults with early Parkinson disease not yet requiring symptomatic treatment, serum urate below the population median (~6 mg/dL), Parkinson Study Group sites, USA
- Participants
- 75
- Comparator
- placebo
- Duration
- 731 days
- Endpoints measured
- 41